Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced an exclusive five-year global supply agreement for NO and NO2 (Nitrogen Dioxide) calibration gas with MESA Specialty Gases & Equipment.
Key Highlights
-
Five year term begins on the earlier of FDA approval for the LungFit™ PH system or December 31, 2020
-
Beyond Air will be responsible for the initial and future costs for adjustments to MESA facilities to meet capacity requirements (estimated to be less than $100,000)
-
Beyond Air has the option to have MESA design and operate a calibration gas manufacturing facility dedicated to Beyond Air
-
Deal is exclusive on a global basis to both companies
Backup Power Is a Lifeline: What Healthcare Facility Managers Must Get Right
3 Pillars of Stronger Cybersecurity in Healthcare
Piedmont Fayette Hospital to Build New Patient Tower
Texas HHSC Announces Construction of New Lubbock Psychiatric Center
Armed Standoff at West Virginia Hospital Reminds of the Need for Safety Measures